Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04217329 and Latanoprost in Glaucoma and Ocular Hypertension
NCT00934089Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2010
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of taprenepag in Open-angle glaucoma (OAG) and ocular hypertension, sponsored by Pfizer. Started Jan 2010; status: completed.
02
Drugs
taprenepag
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00934089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00934089.